UCD National Virus Reference Laboratory

Date of change: w/b 7^th October 2024

Test: NxTAG Respiratory Screen

Test code: LRSC

Reason for Notification

We are suspending routine testing for human metapneumovirus (hMPV), following notice from the assay manufacturer of a risk of false positive results being generated.  We do not currently know when or if this issue will be resolved by the manufacturer.

Changes to Reporting of Results

 Date of Implementation: 17/10/2024 10.00

 Reason for Notification: Operation of the UCD clinical advice and results line reverting to UCD Telephone Services from Blueface (Comcast)

 Temporary NVRL numbers: Will be provided if required. 

Please use current phone number - 01-7164401 

 Please call or email Geoff Gray (geoffrey.gray@ucd.ie) with any queries.

  NVRL reference: CN-24-30

Discontinuation of Artus CMV DNA assay - new Altona CMV DNA assay introduced: week beginning 07th October 2024

Test code: ACMV
Test code: MCMH for the congenital CMV screening programme (urines)

Reason for Notification
The current real-time PCR assay for the detection and quantification of CMV DNA is manufactured
by Artus: however this assay has now been discontinued. The NVRL will switch to an assay provided
by Altona Diagnostics.

NVRL has been notified, by the manufacturer, that the ISAGA Toxoplasma IgA and IgM assays used
to investigate Toxoplasma infection from patients less than 6 months of age are no longer available.
No suitable alternative is currently available for the Toxoplasma IgA and in line with the Toxoplasma
reference unit, UK we will cease offering routine Toxoplasma IgA investigation from today.

 Date of change: 9th September 2024

Test code: MGMR

UCD NVRL will be introducing an assay for Mycoplasma genitalium macrolide drug resistance.   

The new test code is provided above. This will be performed automatically on all M. gen positive specimens, and should not require users to request additional testing.

Fluoroquinolone drug resistance testing will be introduced shortly, but in the meantime, samples showing evidence of macrolide resistance will be referred to the laboratory in PHA Colindale.

Please find below the latest information regarding the assessment and testing pathways for MPXV Clade I and Clade II. This update supersedes all previous communications and can be accessed on the HPSC website. As noted, there is no need to contact the NVRL, either during working hours or after hours, before sending samples for mpox testing. Our user manual will be updated accordingly.